A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study Of Nivolumabversus Placebo In Combination With Neoadjuvant Chemotherapy And Adjuvant Endocrine Therapy In Patients With High-Risk, Estrogen Receptor-Positive (ER+), Human Epidermalgrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Read more
OASIS: Phase II Trial Of Oral SM-88 In Patients With Metastatic Hormone Receptor-Positive HER2-Negative (HR+/HER2-) Breast Cancer. Read more
Phase III Randomized Adjuvant Study Of Pembrolizumab In Muscle Invasive And Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation Read more
Phase II Study Of Front Line Therapy With Nivolumab And Salvage Nivolumab + Ipilimumab In Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260 Read more
A Phase 2 Study Of Cabozantinib In Combination With Atezolizumab As Neoadjuvant Treatment For Muscle-Invasive Bladder Cancer (ABATE) Read more
